Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;99(6):1498-1500.
doi: 10.1016/j.kint.2021.04.005. Epub 2021 Apr 20.

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Ilies Benotmane  1 , Gabriela Gautier-Vargas  2 , Noëlle Cognard  2 , Jérôme Olagne  2 , Françoise Heibel  2 , Laura Braun-Parvez  2 , Jonas Martzloff  2 , Peggy Perrin  2 , Bruno Moulin  3 , Samira Fafi-Kremer  4 , Sophie Caillard  3
Affiliations
Comment

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Ilies Benotmane et al. Kidney Int. 2021 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anti-spike IgG antibody titers (arbitrary unit [AU]/ml) measured after the second injection of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in 204 kidney transplant recipients without a history of coronavirus disease 2019 (COVID-19). Patients with titers >50 AU/ml were considered as seropositive. Bars represent median values. (a) Scattergram showing a significant positive correlation between anti-spike IgG antibody titers (AU/ml) after the first and second vaccine injections (Spearman ρ = 0.68; P < 0.0001). (b) Kidney transplant recipients being treated with antimetabolites (mycophenolate mofetil [MMF]/mycophenolic acid [MPA]) had lower median antibody titers compared with those who did not receive antimetabolites (21.2 [interquartile range {IQR}, 6.8−401.9] AU/ml vs. 147.4 [IQR, 27.5−3352.5] AU/ml, respectively; P = 0.0005). (c) Kidney transplant recipients being treated with steroids had lower median antibody titers compared with those who did not receive steroids (17.9 [IQR, 6.8−378.9] AU/ml vs. 74.8 [IQR, 7.2−2417.9] AU/ml; P = 0.002). (d) Kidney transplant recipients being treated with calcineurin inhibitors (CNIs) had lower median antibody titers compared with those who did not receive CNIs (18.1 [IQR, 6.8−330] AU/ml for patients under tacrolimus and 76.6 [IQR, 10.1−2392.2] AU/ml for patients under cyclosporine vs. 220 [IQR, 6.8−4269] AU/ml for patients who did not receive CNIs). (e) Kidney transplant recipients being treated with tacrolimus + antimetabolites (MMF/MPA) had lower median antibody titers compared with those did not (9.2 [IQR, 6.8−110.2] AU/ml vs. 90.9 [IQR, 7.7−1976] AU/ml, respectively; P < 0.0001). (f) Kidney transplant recipients being treated with tacrolimus + antimetabolites (MMF/MPA) + steroids had lower median antibody titers compared with those who did not (6.8 [IQR, 6.8−57.4] AU/ml vs. 79.4 [IQR, 6.9−1393.5] AU/ml, respectively; P < 0.0001).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Benotmane I., Gautier-Vargas G., Cognard N. Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99:1487–1489. - PMC - PubMed
    1. Boyarsky B.J., Werbel W.A., Avery R.K. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients [e-pub ahead of print]. JAMA. https://doi.org/10.1001/jama.2021.4385 Accessed April 22, 2021. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. Moderna COVID-19 vaccine overview and safety. Updated April 5, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Mo... Available at: Accessed March 10, 2021.
    1. Prendecki M., Clarke C., Brown J. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178–1181. - PMC - PubMed